produce Kaplan-Meier diagrams for our studies, but, unfortunately, they were not published for comparison studies, such as Prados et al. 2 If Vickers reads our recent articles describing survival in antineoplaston clinical trials, published in peer-reviewed journals between 1999 and 2003, he will indeed find Kaplan-Meier data. Our data on the proportion of patients surviving 5 years contain no uncertainty, since they are not estimated but true survivals. The patients are either dead or alive after 5 years. No standard error or confidence intervals are necessary.
The final reports on the studies conducted at the University of Kurume had not yet been published at the time my manuscript was submitted to Integrative Cancer Therapies. Japanese researchers have published preliminary reports and case reports; these were listed as references. The Kurume researchers presented the summary of research data directly to me with permission for publication. I described these as "preliminary results" on page 55 without making any changes. Those researchers are now preparing the final reports for publication.
In conclusion, I believe I have sufficiently answered Vickers's questions regarding the clinical trials conducted by our clinic. Further details will be provided in a number of articles that are now in preparation for publication.
